1311 related articles for article (PubMed ID: 28651018)
21. Exosome-derived microRNAs contribute to prostate cancer chemoresistance.
Li J; Yang X; Guan H; Mizokami A; Keller ET; Xu X; Liu X; Tan J; Hu L; Lu Y; Zhang J
Int J Oncol; 2016 Aug; 49(2):838-46. PubMed ID: 27278879
[TBL] [Abstract][Full Text] [Related]
22. MicroRNAs as prognostic markers in prostate cancer.
Suer I; Guzel E; Karatas OF; Creighton CJ; Ittmann M; Ozen M
Prostate; 2019 Feb; 79(3):265-271. PubMed ID: 30345533
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs.
He H; Wang L; Zhou W; Zhang Z; Wang L; Xu S; Wang D; Dong J; Tang C; Tang H; Yi X; Ge J
PLoS One; 2015; 10(5):e0125672. PubMed ID: 25938468
[TBL] [Abstract][Full Text] [Related]
24. MiRNAs and radical prostatectomy: Current data, bioinformatic analysis and utility as predictors of tumour relapse.
Konoshenko MY; Laktionov PP
Andrology; 2021 Jul; 9(4):1092-1107. PubMed ID: 33638886
[TBL] [Abstract][Full Text] [Related]
25. Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.
Foj L; Filella X
Pathol Oncol Res; 2019 Oct; 25(4):1445-1456. PubMed ID: 30367364
[TBL] [Abstract][Full Text] [Related]
26. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
[TBL] [Abstract][Full Text] [Related]
27. miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer.
Chen R; Sheng L; Zhang HJ; Ji M; Qian WQ
J Cell Mol Med; 2018 Mar; 22(3):1855-1863. PubMed ID: 29363862
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
29. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing.
Song C; Chen H; Wang T; Zhang W; Ru G; Lang J
Prostate; 2015 Apr; 75(5):500-16. PubMed ID: 25597612
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA Expression Profiles, Target Genes, and Pathways in Intervertebral Disk Degeneration: A Meta-Analysis of 3 Microarray Studies.
Sherafatian M; Abdollahpour HR; Ghaffarpasand F; Yaghmaei S; Azadegan M; Heidari M
World Neurosurg; 2019 Jun; 126():389-397. PubMed ID: 30904808
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Pereira TDSF; Brito JAR; Guimarães ALS; Gomes CC; de Lacerda JCT; de Castro WH; Coimbra RS; Diniz MG; Gomez RS
J Oral Pathol Med; 2018 Jan; 47(1):78-85. PubMed ID: 29032608
[TBL] [Abstract][Full Text] [Related]
34. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.
Liu R; Liu C; Zhang D; Liu B; Chen X; Rycaj K; Jeter C; Calhoun-Davis T; Li Y; Yang T; Wang J; Tang DG
Oncotarget; 2016 Aug; 7(35):56628-56642. PubMed ID: 27447749
[TBL] [Abstract][Full Text] [Related]
35. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
36. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
37. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA alteration and putative target genes in high-grade prostatic intraepithelial neoplasia and prostate cancer: STAT3 and ZEB1 are upregulated during prostate carcinogenesis.
Cha YJ; Lee JH; Han HH; Kim BG; Kang S; Choi YD; Cho NH
Prostate; 2016 Jul; 76(10):937-47. PubMed ID: 27017949
[TBL] [Abstract][Full Text] [Related]
39. miR-93-5p may be an important oncogene in prostate cancer by bioinformatics analysis.
Yang Y; Jia B; Zhao X; Wang Y; Ye W
J Cell Biochem; 2019 Jun; 120(6):10463-10483. PubMed ID: 30582208
[TBL] [Abstract][Full Text] [Related]
40. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.
Fuse M; Kojima S; Enokida H; Chiyomaru T; Yoshino H; Nohata N; Kinoshita T; Sakamoto S; Naya Y; Nakagawa M; Ichikawa T; Seki N
J Hum Genet; 2012 Nov; 57(11):691-9. PubMed ID: 22854542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
